paidher

Cougar Biotechnology: Stalking Prostate Cancer

<<Provenge seems to work well only in a subset of the HRPC patients.>>

Bryan,
I don't know which subset of HRPC patients are you referring to?

Critics of Provenge who contend the survival benefits of Provenge aren’t robust enough to warrant FDA marketing approval demean the human reality.

We know that patients who received Provenge had a 4.5 month median survival advantage than that reported for the placebo arm. Nearly twice as effective as Taxotere’s 2.3 month survival benefit. Even more impressive, patients that received Provenge followed by Taxotere where shown to increase their median survival to 35 months.

Yet, the survival advantages for Taxotere are enough to garner FDA marketing approval but not for Provenge? Taxotere showed a lower survival advantage and significantly adverse side effects when compared Provenge.

Without question, there is a large unmet medical need. Each year approximately 50,000 men die from prostate cancer. Yet, the only FDA approved treatment for end stage prostate cancer in 45 years has been Taxotere.

These barriers to reason must not stand. We must bring truth and reason to power in the public arena. I pray for change at the highest levels of the FDA.